Affiliation:
1. Biotechnology Institute, School of Environment and Chemical Engineering, Dalian Jiaotong University, Dalian 116028, China | Institute of Molecular Plant Science, University of Edinburgh, Edinburgh EH9 3BF, UK
2. Biotechnology Institute, School of Environment and Chemical Engineering, Dalian Jiaotong University, Dalian 116028, China
3. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Beijing 100193, China
Abstract
Background:
The representative anti-COVID-19 herbs, i.e., Poriacocos, Pogostemon, Prunus, and
Glycyrrhiza plants, are commonly used in the prevention and treatment of COVID-19, a pandemic caused by SARSCoV-
2. Diverse medicinal compounds with favorable anti-COVID-19 activities are abundant in these plants, and
their unique pharmacological/pharmacokinetic properties have been revealed. However, the current trends in drug
metabolism/pharmacokinetic (DMPK) investigations of anti-COVID-19 herbs have not been systematically summarized.
Methods:
In this study, the latest awareness, as well as the perception gaps regarding DMPK attributes, in the anti-
COVID-19 drug development and clinical usage was critically examined and discussed.
Results:
The extracts and compounds of P.cocos, Pogostemon, Prunus, and Glycyrrhiza plants show distinct and
diverse absorption, distribution, metabolism, excretion, and toxicity (ADME/T) properties. The complicated herbherb
interactions (HHIs) and herb-drug interactions (HDIs) of anti-COVID-19 Traditional Chinese Medicine (TCM)
herb pair/formula dramatically influence the PK/pharmacodynamic (PD) performance of compounds thereof, which
may inspire researchers to design innovative herbal/compound formulas for optimizing the therapeutic outcome of
COVID-19 and related epidemic diseases. The ADME/T of some abundant compounds in anti-COVID-19 plants
have been elucidated, but DMPK studies should be extended to more compounds of different medicinal parts, species,
and formulations and would be facilitated by various omics platforms and computational analyses.
Conclusion:
In the framework of pharmacology and pharmacophylogeny, the DMPK knowledge base would promote
the translation of bench findings into the clinical practice of anti-COVID-19 and speed up the anti-COVID-19
drug discovery and development.
Funder
Scientific Research Funds Project of the Liaoning Education Department
China Scholarship Council
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference122 articles.
1. Huang W.; Rao Y.L.; Sun Q.G.; Li C.Y.; Ba Y.M.; Study on medication laws of traditional Chinese medicine of 340 cases of COVID-19 based on data mining. Hainan Yixueyuan Xuebao 2020,26(12),881-888
2. Stukalov A.; Girault V.; Grass V.; Karayel O.; Bergant V.; Urban C.; Haas D.A.; Huang Y.; Oubraham L.; Wang A.; Hamad M.S.; Piras A.; Hansen F.M.; Tanzer M.C.; Paron I.; Zinzula L.; Engleitner T.; Reinecke M.; Lavacca T.M.; Ehmann R.; Wölfel R.; Jores J.; Kuster B.; Protzer U.; Rad R.; Ziebuhr J.; Thiel V.; Scaturro P.; Mann M.; Pichlmair A.; Multilevel proteomics reveals host pertur-bations by SARS-CoV-2 and SARS-CoV. Nature 2021,594(7862),246-252
3. de Wit E.; van Doremalen N.; Falzarano D.; Munster V.J.; SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol 2016,14(8),523-534
4. Yang Y.J.; X.H., E.; Ren, H.W.; He, Y.; Zhou, S.P. Consideration of traditional Chinese medicine in treatment of highly pathogenic human coronaviruses SARS-CoV-2 and SARS-CoV. Chin Tradit Herbal Drugs 2020,51(6),1427-1434
5. Wang C.; Ming H.; Jia W.; Su W.; Zhan L.R.; Luo D.; Yang J.Y.; [Analysis of medication regularity and pharmacodynamic characteris-tics of traditional Chinese medicine treatment in 444 severe cases of COVID-19]. Zhongguo Zhongyao Zazhi 2020,45(13),3007-3012
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献